Finance
Dialysis firm FMC delivers profit beat on cost cuts, even as flu mortality effects linger
Published by Global Banking and Finance Review
Posted on November 4, 2025
Global Banking and Finance Review
Company
Global Banking and Finance Review is an online platform offering news, analysis, and opinion on the latest trends, developments, and innovations in the banking and finance industry worldwide. The platform covers a diverse range of topics, including banking, insurance, investment, wealth management, fintech, and regulatory issues. The website publishes news, press releases, opinion and advertorials on various financial organizations, products and services which are commissioned from various Companies, Organizations, PR agencies, Bloggers etc. These commissioned articles are commercial in nature. This is not to be considered as financial advice and should be considered only for information purposes. It does not reflect the views or opinion of our website and is not to be considered an endorsement or a recommendation. We cannot guarantee the accuracy or applicability of any information provided with respect to your individual or personal circumstances. Please seek Professional advice from a qualified professional before making any financial decisions. We link to various third-party websites, affiliate sales networks, and to our advertising partners websites. When you view or click on certain links available on our articles, our partners may compensate us for displaying the content to you or make a purchase or fill a form. This will not incur any additional charges to you. To make things simpler for you to identity or distinguish advertised or sponsored articles or links, you may consider all articles or links hosted on our site as a commercial article placement. We will not be responsible for any loss you may suffer as a result of any omission or inaccuracy on the website.
Published by Global Banking and Finance Review
Posted on November 4, 2025
By Maria Rugamer, Patricia Weiss and Bartosz Dabrowski
(Reuters) -Fresenius Medical Care posted a stronger-than-expected quarterly operating income on Tuesday, helped by cost savings and portfolio measures, but kept its outlook unchanged amid lingering effects from elevated flu mortality among patients.
The dialysis specialist, which makes a bulk of its revenue in the United States, reported an operating income excluding special items of 574 million euros ($669 million) for the third quarter, beating a company-provided consensus of 550 million euros.
Elevated mortality from an unusually severe flu season in the U.S. had led to disappointing second-quarter results and continues to be a drag, CEO Helen Giza told Reuters, even though the past quarter was "as normal as you get".
"You're still dealing with the annualization of the patients lost in the early part of the year," she said.
The Germany-based company is on track to meet its 2025 targets after delivering 174 million euros in savings from its cost-cutting programme in the first nine months of the year, just shy of the 180 million euro full-year goal, Giza said in a statement.
The strategy, which aims to unlock up to 1.05 billion euros in annual savings by 2027, helped the group lift its adjusted operating income by 28% in the third quarter.
Giza also said she was confident FMC would return to a pre-pandemic growth rate of 2%, but did not provide a timeline for that.
But despite what J.P. Morgan analyst David Adlington described as "potentially decent" results, FMC's shares fell nearly 6.5% and were on track for their worst day since early March as of 1000 GMT.
The market is expected to remain cautious due to the risk of another significant share sale by FMC's former parent Fresenius, Adlington added.
FMC kicked off a 1-billion-euro share buyback programme in August and had repurchased 3.6 million shares for 151 million euros by the end of the third quarter.
($1 = 0.8575 euros)
(Reporting by Maria Rugamer and Bartosz Dabrowski in Gdansk, Patricia Weiss in Frankfurt, editing by Milla Nissi-Prussak)